Screenings Needed for your Patients on Antipsychotic Therapies
Schizophrenia and bipolar disorder are associated with increased morbidity and mortality from cardiovascular disorders and diabetes mellitus. The use of antipsychotic medications in the treatment of schizophrenia, bipolar and other conditions further elevates the risk of obesity, diabetes, high cholesterol, high blood pressure, insulin resistance and other cardiometabolic disorders.
If any of your patients are being treated with antipsychotic medications, please contact those patients who have not yet been screened for diabetes (blood glucose or HbA1c) and LDL-C, weight and BMI to schedule an annual appointment for these screenings. For your convenience, treatment guidelines for both bipolar disorder and schizophrenia can be found on our website, as well as at ValueOptions®, which manages behavioral health services for EmblemHealth members.
Your patients may be eligible to participate in the Intensive Case Management Program administered by ValueOptions. This confidential program is offered at no additional cost to our members. Enrolled patients are assigned a case manager who will work with practitioners to assist with medication adherence, behavioral and medical treatment plan compliance to help the patient stay out of the hospital. To refer a patient to the Case Management Program, please call 1-855-589-2773, option 3.
The American Diabetes Association has developed education materials for clinicians, patients and caregivers to help them better understand the issues related to antipsychotic drug therapy in patients who may have or may be at risk for diabetes or cardiovascular disease.